![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/jacobio-pharma-presents-shp2-plus-kras-g12c-data-at-asco-302161187.html
https://pharmaphorum.com/news/jacobio-plans-bid-chinas-kras-market-safety-edge
https://www.prnewswire.com/news-releases/jacobio-pharma-announced-its-kras-g12c-inhibitor-reached-the-primary-endpoint-302132417.html
https://www.prnewswire.com/news-releases/jacobio-pharma-to-present-data-of-parp7-inhibitor-and-p53-reactivator-at-the-2024-aacr-annual-meeting-302111713.html
https://www.prnewswire.com/news-releases/jacobio-pharma-announces-2023-annual-results-302103241.html
https://www.prnewswire.com/news-releases/jacobio-pharma-receives-ind-approval-for-p53-y220c-activator-jab-30300-in-the-us-302076832.html
https://www.prnewswire.com/news-releases/jacobio-announces-china-cde-clearance-for-phase-iii-clinical-trial-of-shp2-inhibitor-plus-kras-g12c-inhibitor-302064689.html
https://www.prnewswire.com/news-releases/jacobio-pharma-presents-clinical-results-of-glecirasib-in-combination-with-jab-3312-at-esmo-301963816.html
https://www.prnewswire.com/news-releases/jacobio-pharma-announces-breakthrough-therapy-designation-from-china-cde-for-kras-g12c-inhibitor-glecirasib-for-the-treatment-of-pancreatic-cancer-301894504.html
https://www.prnewswire.com/news-releases/jacobio-pharma-to-present-data-of-glecirasib-in-combination-with-jab-3312-at-the-2023-esmo-conference-301882722.html